Infant health and neurodevelopmental outcomes following prenatal exposure to duloxetine. (Q45949600)

18 December 2017

title

Infant health and neurodevelopmental outcomes following prenatal exposure to duloxetine. (English)

1 reference

18 December 2017

1 reference

Cesario Bellantuono

1 reference

18 December 2017

Alessandra Marini

series ordinal

1 reference

18 December 2017

Chiara Lucarelli

series ordinal

1 reference

18 December 2017

publication date

1 September 2013

1 reference

18 December 2017

Clinical Drug Investigation

published in

1 reference

18 December 2017

volume

1 reference

18 December 2017

issue

1 reference

18 December 2017

page(s)

685-688

1 reference

18 December 2017

The general and comparative efficacy and safety of duloxetine in major depressive disorder: a systematic review and meta-analysis

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0112-Y

Duloxetine: a review of its use in the treatment of generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0112-Y

Duloxetine transfer across the placenta during pregnancy and into milk during lactation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0112-Y

Use of duloxetine in pregnancy and lactation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0112-Y

Poor neonatal adaptation after in utero exposure to duloxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0112-Y

Placental transfer of SSRI and SNRI antidepressants and effects on the neonate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0112-Y

A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0112-Y

Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0112-Y

Antidepressant use in pregnancy: a critical review focused on risks and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0112-Y

In utero antidepressant exposure and neurodevelopment in preterm infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0112-Y

Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0112-Y

The Dubowitz neurological examination of the full-term newborn

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0112-Y

Prenatal depression effects on the fetus and newborn: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0112-Y

The impact of maternal depression in pregnancy on early child development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0112-Y

A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0112-Y

Antidepressant use during pregnancy: a critical systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0112-Y

Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0112-Y

Rates of major malformations in infants following exposure to duloxetine during pregnancy: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0112-Y

Duloxetine and pregnancy outcomes: safety surveillance findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0112-Y

Relative impact of maternal depression and associated risk factors on offspring psychopathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0112-Y

Untreated prenatal maternal depression and the potential risks to offspring: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0112-Y

Antidepressant treatment during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0112-Y

Pharmacokinetics of duloxetine in breast milk and plasma of healthy postpartum women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0112-Y

Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0112-Y

Depression during Pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0112-Y

Maternal trait anxiety, depression and life event stress in pregnancy: relationships with infant temperament

21 January 2018

1 reference

12 December 2020

[Presentation of a French scale of tests for infants]

1 reference

12 December 2020

Depression during Pregnancy : Overview of Clinical Factors

1 reference

12 December 2020

On categorizing gestational, birth, and neonatal complications following late pregnancy exposure to antidepressants: the prenatal antidepressant exposure syndrome.

1 reference

12 December 2020

10.1007/S40261-013-0112-Y

Identifiers

DOI

1 reference

18 December 2017

1 reference

18 December 2017